New research on breast cancer biopsies and counseling after treatment will allow surgeons to have more meaningful conversations with their patients, according to a study published in JAMA Surgery.
New research on breast cancer biopsies and counseling after treatment will allow surgeons to have more meaningful conversations with their patients, according to a study published in JAMA Surgery.
In 2017, the American Cancer Society recorded 252,710 women diagnosed with breast cancer, while 63,410 were diagnosed during the early stages of the disease.
“This is a genuine concern for patients. Many feel very anxious over the future need for biopsies and the potential of another diagnosis,” Henry Kuerer, MD, PhD, the study’s corresponding author, said in a statement. “Women will often choose a mastectomy rather than have the fear and stress associated with future biopsies or another cancer diagnosis.”
After a review of previous literature, Kuerer said that data were not recorded that analyzed breast cancer recurrence rates and how often cancer will develop in the second breast after treating the first breast.
Kuerer and colleagues at The University of Texas MD Anderson Cancer Center analyzed 120,000 women diagnosed and treated for early-stage breast cancer to determine the possibility of additional breast biopsies patients will need during follow-up care.
The study incorporated 2 national databases—MarketScan and SEER-Medicare—that included 41,510 breast cancer patients in the first database and 80,369 in the second. Patients included in the study were diagnosed with stage I to III of the disease between 2000 and 2011. MarketScan includes patients with private insurance who are 64 years and younger and SEER-Medicare includes patients over the age 65.
The 5- and 10-year overall incidence of breast biopsy was recorded. The MarketScan cohort saw incidence rates of 14.7% at 5 years and 23.4% at 10 years. SEER-Medicare patients saw an incidence rate of 11.8% at 5 years and 14.9 % at 10 years.
The researchers found that the 5-year incidence of breast biopsy was higher in women treated with brachytherapy than those who underwent whole-breast radiation. After a mastectomy in one breast, the 5-year biopsy rates for the other breast were 10.4% in the MarketScan group and 7.8% for the SEER-Medicare group.
“This information is something I can use daily when discussing breast cancer treatment options,” Kuerer said. “The important message is that the rate of biopsy for patients is relatively low and the overwhelming majority of the biopsy results will be benign and not require further treatment.”
This study is assisting additional research conducted by MD Anderson that evaluates the need for surgery in patients diagnosed with early-stage breast cancer who achieve a pathological complete response to chemotherapy or targeted therapy.
References
Van la Parra RFD, Liao K, Smith BD, et al. Incidence and outcome of breast biopsy procedures during follow-up after treatment for breast cancer. JAMA Surg. Published online January 31, 2018. doi:10.1001/jamasurg.2017.5572.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More